Deoxyshikonin inhibits cisplatin resistance of non–small‐cell lung cancer cells by repressing Akt‐mediated ABCB1 expression and function

CHD1L contributes to cisplatin resistance by upregulating the ABCB1–NF-κB axis in human non-small-cell lung cancer

(2019) Yang Li et al.   Cell Death & Disease

The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling

(2019) Dong-ming Wu et al.   Cell Death & Disease

Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018

(2019) Haval Balata et al.   Journal of Thoracic Oncology

Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness

(2019) Michela Terlizzi et al.   PHARMACOLOGY & THERAPEUTICS

Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways

(2019) Bin Zhu et al.   BIOCHEMICAL PHARMACOLOGY

HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells

(2018) Ying Li et al.   GENE

Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway

(2018) Tianxiao Gong et al.   Journal of Translational Medicine

Beneficial Effects of Deoxyshikonin on Delayed Wound Healing in Diabetic Mice

(2018) Jun Park et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Gastrointestinal Hormone Cholecystokinin Increases P-Glycoprotein Membrane Localization and Transport Activity in Caco-2 Cells

(2017) Kentaro Yano et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Lung cancer: current therapies and new targeted treatments

(2017) Fred R Hirsch et al.   LANCET

Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

(2017) Cristina Pérez-Ramírez et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis

(2017) Pei Wang et al.   OncoTargets and Therapy

Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients

(2016) Cristina Pérez-Ramírez et al.   PHARMACOLOGICAL RESEARCH

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

(2016) Cristian Massacesi et al.   OncoTargets and Therapy

Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib

(2015) Qiaoli Zhao et al.   INTERNATIONAL JOURNAL OF CANCER

PTEN and PI3K/AKT in non-small-cell lung cancer

(2015) Cristina Pérez-Ramírez et al.   PHARMACOGENOMICS

Targeting apoptosis for anticancer therapy

(2015) Simone Fulda   SEMINARS IN CANCER BIOLOGY

Non-small-cell lung cancer

(2015) Cesare Gridelli et al.   Nature Reviews Disease Primers

Autophagy delays apoptosis in renal tubular epithelial cells in cisplatin cytotoxicity

(2014) Gur P. Kaushal et al.   Autophagy

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

(2014) Claudia Fumarola et al.   BIOCHEMICAL PHARMACOLOGY

Prognostic value of phospho-Akt in patients with non-small cell lung carcinoma: A meta-analysis

(2014) Yang Yang et al.   INTERNATIONAL JOURNAL OF CANCER

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data

(2014) Antonio Rossi et al.   LANCET ONCOLOGY

Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer

(2014) Maimon C. Rose et al.   GENOMICS PROTEOMICS & BIOINFORMATICS

New Insight into P-Glycoprotein as a Drug Target

(2012) Albert Breier et al.   Anti-Cancer Agents in Medicinal Chemistry

In vitro and in vivo anticancer effects of Lithospermum erythrorhizon extract on B16F10 murine melanoma

(2012) Seetharaman Rajasekar et al.   JOURNAL OF ETHNOPHARMACOLOGY

Naturally-occurring shikonin analogues – A class of necroptotic inducers that circumvent cancer drug resistance

(2008) Yanyan Xuan et al.   CANCER LETTERS